The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)
Condition(s):Pulmonary LymphangioleiomyomatosisLast Updated:November 30, 2016Completed
Hide Studies Not Open or Pending
Condition(s):Pulmonary LymphangioleiomyomatosisLast Updated:November 30, 2016Completed
Condition(s):Pulmonary LymphangioleiomyomatosisLast Updated:July 30, 2020Terminated
Condition(s):Alcohol DrinkingLast Updated:January 14, 2020Completed
Condition(s):Fibrodysplasia Ossificans ProgressivaLast Updated:July 22, 2022Recruiting
Condition(s):Recurrent Melanoma; Stage IIA Melanoma; Stage IIB Melanoma; Stage IIC Melanoma; Stage IV MelanomaLast Updated:May 21, 2014Completed
Condition(s):Alcohol DrinkingLast Updated:November 13, 2020Completed
Condition(s):Adenocarcinoma of the Gastroesophageal Junction; Adenocarcinoma of the Stomach; Recurrent Gastric Cancer; Stage III Gastric Cancer; Stage III Esophageal Cancer; Stage IV Esophageal Cancer; Stage IV Gastric CancerLast Updated:August 23, 2018Completed
Condition(s):Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung CancerLast Updated:August 29, 2018Completed
Condition(s):Extensive Stage Small Cell Lung Cancer; Lung Metastases; Malignant Pleural Effusion; Recurrent Small Cell Lung CancerLast Updated:December 7, 2017Completed
Condition(s):Invasive Thymoma and Thymic Carcinoma; Recurrent Thymoma and Thymic Carcinoma; Stage III Thymoma; Stage IVA Thymoma; Stage IVB ThymomaLast Updated:June 10, 2015Terminated
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.